Global MSI-H/dMMR Market By Treatment Type (Immune Checkpoint Inhibitors (ICIs) and Combination Therapy), By Stage (Early Stages (Stage I and II) and Advanced Stages (Stage III and IV)), By Indication (Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer and Others), By End-User (Hospitals, Oncology Clinics, Research Institutions, and Homecare), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034
- Published date: March 2025
- Report ID: 140940
- Number of Pages: 200
- Format:
-
keyboard_arrow_up
-
-
- Pfizer Inc Company Profile
- Merck & Co.
- AstraZeneca Plc Company Profile
- F. Hoffmann-La Roche Ltd
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- GSK plc.
- BeiGene LTD.
- Summit Therapeutics Inc.
- Sanofi Company Profile
- Novartis AG Company Profile
- AbbVie Inc. Company Profile
- Amgen Inc.
- Johnson & Johnson Services, Inc.
- settingsSettings
Our Clients
- 140940
- March 2025
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
|
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
|---|---|---|---|
| e-Access | |||
| Report Library Access | |||
| Data Set (Excel) | |||
| Company Profile Library Access | |||
| Interactive Dashboard | |||
| Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
| Accessibility | 1 User | 2-5 User | Unlimited |
| Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
| Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
| Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |
